Lindbrook Capital’s Cytek Biosciences CTKB Stock Holding History

Lindbrook Capital’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-94	Closed	-$610	–	2814
2024 Q4	$610	Buy	+94	New	+$560	﹤0.01%	2575

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lindbrook Capital's CTKB Position: Q1 2025 in Review

Lindbrook Capital sold out of Cytek Biosciences (CTKB) in Q1 2025, closing a stake of 94 shares — an estimated $610 sold.

Lindbrook Capital first reported a position in CTKB in Q4 2024 and held it in 1 quarter. The position peaked at $610 in Q4 2024. 160 funds tracked by Wall St. Rank hold CTKB as of Q1 2025.

Lindbrook Capital reported no remaining Cytek Biosciences position as of Q1 2025 after selling out during the quarter.
Lindbrook Capital sold 94 Cytek Biosciences shares in Q1 2025, an estimated $610.
Lindbrook Capital first reported a position in Cytek Biosciences in Q4 2024 and held it in 1 quarter.
Lindbrook Capital's Cytek Biosciences position peaked at $610 in Q4 2024.
160 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.